After four years of prasugrel therapy following the initial stent placement and a repeat stent for restenosis, can the prasugrel be discontinued and the patient remain on aspirin alone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Prasugrel Be Discontinued After 4 Years?

Yes, prasugrel can be discontinued after 4 years of therapy following your stent procedures, and you should continue aspirin monotherapy indefinitely. At this point, you have far exceeded the guideline-recommended duration of dual antiplatelet therapy (DAPT).

Guideline-Recommended Duration

The standard duration of DAPT after stent placement is well-established:

  • For ACS patients (which includes in-stent restenosis): P2Y12 inhibitor therapy (including prasugrel) should be given for at least 12 months 1, 2, 3
  • Beyond 12 months: Continuation may be considered but is optional (Class IIb recommendation) 2, 4, 3

The 2017 ESC guidelines specifically state that DAPT duration decisions should be dynamic and reassessed during treatment, with consideration for discontinuation after 6 months in patients with high bleeding risk 1.

Why 4 Years Exceeds Recommendations

Your 4-year duration of prasugrel therapy is more than 3 times longer than the minimum recommended duration. The evidence supporting extended DAPT beyond 12 months comes primarily from studies examining 30-month therapy, not indefinite continuation 5, 6. Even in these extended duration studies:

  • The DAPT study showed that while 30 months reduced stent thrombosis and MI compared to 12 months, it increased bleeding risk and showed a trend toward increased mortality 5
  • Benefits must be weighed against bleeding risks, which accumulate over time

Transition Strategy

Discontinue prasugrel and continue aspirin 81 mg daily indefinitely 1, 2, 4:

  • Aspirin should be continued lifelong after any coronary stent procedure 2, 4, 3
  • The recommended aspirin dose is 75-100 mg (typically 81 mg in the US) 1, 2
  • No tapering of prasugrel is required; it can be stopped abruptly

Important Caveats

Monitor for symptoms after discontinuation: There is evidence that MI rates can increase within 90 days after stopping P2Y12 inhibitors, even after extended therapy 5, 6. Watch for:

  • New or worsening chest pain
  • Shortness of breath
  • Any symptoms suggesting cardiac ischemia

Consider bleeding risk factors you may have: The FDA label warns that prasugrel carries significant bleeding risk, particularly with prolonged use 7. Continuing beyond 4 years only increases cumulative bleeding exposure without established benefit.

Ensure no recent ACS events: If you've had any acute coronary events in the past 12 months, discuss timing with your cardiologist, as this would restart the DAPT clock.

Bottom Line

After 4 years of prasugrel following your stent procedures, you have completed more than adequate DAPT duration. Discontinue prasugrel and maintain aspirin 81 mg daily indefinitely. The risk-benefit ratio at this point favors stopping the P2Y12 inhibitor, as bleeding risks accumulate while incremental anti-ischemic benefits beyond 12-30 months are not established.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.